flâneur

Pearl Freier on X: "Cell & gene therapies were 2.5x more likely to receive FDA approval after entering Phase 1 than other drug types according to research by the NEWDIGs initiative at Tufts Medical Center h/t @DrPHanley & @alliancerm . @NatRevDrugDisc paper below 1/n https://t.co/DN4k7qWrAt" / X

x.com · 48 words · saved by 1 readers

To view keyboard shortcuts, press question mark View keyboard shortcuts Messages Home Explore Notifications Messages Grok Premium Lists Bookmarks Jobs Communities Verified Orgs Profile More Post Lada Nuzhna @LNuzhna Post See new posts Conversation Pearl Freier @PearlF Cell & gene therapies were 2.5x more likely to receive FDA approval after entering Phase 1 than other drug types according to research by the NEWDIGs initiative at Tufts Medical Center h/t @DrPHanley & @alliancerm . @NatRevDrugDisc paper below 1/n 7:52 AM · Apr 2, 2025 · 4,478 Views 2 7 21 11 Who can reply? Accounts @PearlF follows or mentioned can reply Pearl Freier @PearlF · 8h Here's the @NatRevDrugDisc paper referenced above: Clinical development success rates for durable cell and gene therapies From nature.com 1 245 Patrick J. Hanley @DrPHanley · 6h Thanks for the tag - what a great paper coming out amidst the tragic chaos 2 61 Relevant people Pearl Freier @PearlF Follow Founder of Cambridge BioPartners, In

@PearlF: Cell & gene therapies were 2.5x more likely to receive FDA approval after entering Phase 1 than other drug types according to research by the NEWDIGs initiative at Tufts Medical Center h/t @DrPHanley & @alliancerm . @NatRevDrugDisc paper below 1/n @PearlF: Here's the @NatRevDrugDisc paper referenced above:

saved by

related reading